Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

NEW YORK, December 02, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company ...

NEW YORK - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a biopharmaceutical company focused on developing treatments for brain health disorders, has been selected to join the Nasdaq Biotechnology ...

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...